Toll Free: 1-888-928-9744

Hepatocellular Carcinoma - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 969 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatocellular Carcinoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatocellular Carcinoma - Pipeline Review, H1 2016', provides an overview of the Hepatocellular Carcinoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma
- The report reviews pipeline therapeutics for Hepatocellular Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hepatocellular Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Hepatocellular Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 8 Hepatocellular Carcinoma Overview 9 Therapeutics Development 10 Hepatocellular Carcinoma - Therapeutics under Development by Companies 12 Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes 22 Hepatocellular Carcinoma - Pipeline Products Glance 24 Hepatocellular Carcinoma - Products under Development by Companies 27 Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes 40 Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 42 Hepatocellular Carcinoma - Therapeutics Assessment 171 Drug Profiles 192 Hepatocellular Carcinoma - Recent Pipeline Updates 612 Hepatocellular Carcinoma - Dormant Projects 915 Hepatocellular Carcinoma - Discontinued Products 926 Hepatocellular Carcinoma - Product Development Milestones 929 Appendix 944
List of Tables
Number of Products under Development for Hepatocellular Carcinoma, H1 2016 34 Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H1 2016 35 Number of Products under Development by Companies, H1 2016 36 Number of Products under Development by Companies, H1 2016 (Contd..1) 37 Number of Products under Development by Companies, H1 2016 (Contd..2) 38 Number of Products under Development by Companies, H1 2016 (Contd..3) 39 Number of Products under Development by Companies, H1 2016 (Contd..4) 40 Number of Products under Development by Companies, H1 2016 (Contd..5) 41 Number of Products under Development by Companies, H1 2016 (Contd..6) 42 Number of Products under Development by Companies, H1 2016 (Contd..7) 43 Number of Products under Development by Companies, H1 2016 (Contd..8) 44 Number of Products under Development by Companies, H1 2016 (Contd..9) 45 Number of Products under Investigation by Universities/Institutes, H1 2016 46 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 47 Comparative Analysis by Late Stage Development, H1 2016 48 Comparative Analysis by Clinical Stage Development, H1 2016 49 Comparative Analysis by Early Stage Development, H1 2016 50 Products under Development by Companies, H1 2016 51 Products under Development by Companies, H1 2016 (Contd..1) 52 Products under Development by Companies, H1 2016 (Contd..2) 53 Products under Development by Companies, H1 2016 (Contd..3) 54 Products under Development by Companies, H1 2016 (Contd..4) 55 Products under Development by Companies, H1 2016 (Contd..5) 56 Products under Development by Companies, H1 2016 (Contd..6) 57 Products under Development by Companies, H1 2016 (Contd..7) 58 Products under Development by Companies, H1 2016 (Contd..8) 59 Products under Development by Companies, H1 2016 (Contd..9) 60 Products under Development by Companies, H1 2016 (Contd..10) 61 Products under Development by Companies, H1 2016 (Contd..11) 62 Products under Development by Companies, H1 2016 (Contd..12) 63 Products under Investigation by Universities/Institutes, H1 2016 64 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 65 Hepatocellular Carcinoma - Pipeline by 4SC AG, H1 2016 66 Hepatocellular Carcinoma - Pipeline by AB Science SA, H1 2016 67 Hepatocellular Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016 68 Hepatocellular Carcinoma - Pipeline by ACROVIS Pharma AG, H1 2016 69 Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 70 Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories, LLC, H1 2016 71 Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H1 2016 72 Hepatocellular Carcinoma - Pipeline by Amgen Inc., H1 2016 73 Hepatocellular Carcinoma - Pipeline by AndroScience Corporation, H1 2016 74 Hepatocellular Carcinoma - Pipeline by Arbutus Biopharma Corporation, H1 2016 75 Hepatocellular Carcinoma - Pipeline by ArQule, Inc., H1 2016 76 Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc., H1 2016 77 Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 78 Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2016 79 Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 80 Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2016 81 Hepatocellular Carcinoma - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 82 Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 83 Hepatocellular Carcinoma - Pipeline by Bioneer Corporation, H1 2016 84 Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corporation, H1 2016 85 Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 86 Hepatocellular Carcinoma - Pipeline by Boston Biomedical, Inc., H1 2016 87 Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 88 Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd., H1 2016 89 Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc., H1 2016 90 Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1 2016 91 Hepatocellular Carcinoma - Pipeline by Celgene Corporation, H1 2016 92 Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 93 Hepatocellular Carcinoma - Pipeline by Celsion Corporation, H1 2016 94 Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Limited, H1 2016 95 Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Limited, H1 2016 96 Hepatocellular Carcinoma - Pipeline by CytRx Corporation, H1 2016 97 Hepatocellular Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 98 Hepatocellular Carcinoma - Pipeline by Delcath Systems, Inc., H1 2016 99 Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 100 Hepatocellular Carcinoma - Pipeline by Digna Biotech, S.L., H1 2016 101 Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 102 Hepatocellular Carcinoma - Pipeline by e-Therapeutics Plc, H1 2016 103 Hepatocellular Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016 104 Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H1 2016 105 Hepatocellular Carcinoma - Pipeline by Endocyte, Inc., H1 2016 106 Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H1 2016 107 Hepatocellular Carcinoma - Pipeline by Exelixis, Inc., H1 2016 108 Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 109 Hepatocellular Carcinoma - Pipeline by Genelux Corporation, H1 2016 110 Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1 2016 111 Hepatocellular Carcinoma - Pipeline by Genosco, H1 2016 112 Hepatocellular Carcinoma - Pipeline by GenSpera, Inc., H1 2016 113 Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016 114 Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp., H1 2016 115 Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corporation, H1 2016 116 Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc., H1 2016 117 Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 118 Hepatocellular Carcinoma - Pipeline by HEC Pharm Co., Ltd., H1 2016 119 Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016 120 Hepatocellular Carcinoma - Pipeline by Huperion Sarl, H1 2016 121 Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1 2016 122 Hepatocellular Carcinoma - Pipeline by Immunitor, Inc., H1 2016 123 Hepatocellular Carcinoma - Pipeline by Immunomedics, Inc., H1 2016 124 Hepatocellular Carcinoma - Pipeline by Immunovative Therapies, Ltd., H1 2016 125 Hepatocellular Carcinoma - Pipeline by In-Cell-Art S.A.S., H1 2016 126 Hepatocellular Carcinoma - Pipeline by Incuron, LLC, H1 2016 127 Hepatocellular Carcinoma - Pipeline by InteRNA Technologies B.V., H1 2016 128 Hepatocellular Carcinoma - Pipeline by Jenrin Discovery, Inc., H1 2016 129 Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H1 2016 130 Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd., H1 2016 131 Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H1 2016 132 Hepatocellular Carcinoma - Pipeline by Kite Pharma, Inc., H1 2016 133 Hepatocellular Carcinoma - Pipeline by Komipharm International Co., Ltd., H1 2016 134 Hepatocellular Carcinoma - Pipeline by Kowa Company, Ltd., H1 2016 135 Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H1 2016 136 Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 137 Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 138 Hepatocellular Carcinoma - Pipeline by MaxCyte, Inc., H1 2016 139 Hepatocellular Carcinoma - Pipeline by MedImmune, LLC, H1 2016 140 Hepatocellular Carcinoma - Pipeline by Medivation, Inc., H1 2016 141 Hepatocellular Carcinoma - Pipeline by Medivir AB, H1 2016 142 Hepatocellular Carcinoma - Pipeline by Merck KGaA, H1 2016 143 Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 144 Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 145 Hepatocellular Carcinoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 146 Hepatocellular Carcinoma - Pipeline by Molecular Partners AG, H1 2016 147 Hepatocellular Carcinoma - Pipeline by MolMed S.p.A., H1 2016 148 Hepatocellular Carcinoma - Pipeline by MultiCell Technologies, Inc., H1 2016 149 Hepatocellular Carcinoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016 150 Hepatocellular Carcinoma - Pipeline by NormOxys, Inc., H1 2016 151 Hepatocellular Carcinoma - Pipeline by Novartis AG, H1 2016 152 Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 153 Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corporation, H1 2016 154 Hepatocellular Carcinoma - Pipeline by Omeros Corporation, H1 2016 155 Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc., H1 2016 156 Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 157 Hepatocellular Carcinoma - Pipeline by OncoTherapy Science, Inc., H1 2016 158 Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 159 Hepatocellular Carcinoma - Pipeline by Onxeo SA, H1 2016 160 Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 161 Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 162 Hepatocellular Carcinoma - Pipeline by Pfizer Inc., H1 2016 163 Hepatocellular Carcinoma - Pipeline by Pharma Mar, S.A., H1 2016 164 Hepatocellular Carcinoma - Pipeline by PharmAbcine, Inc., H1 2016 165 Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corporation, H1 2016 166 Hepatocellular Carcinoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 167 Hepatocellular Carcinoma - Pipeline by Progen Pharmaceuticals Limited, H1 2016 168 Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H1 2016 169 Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 170 Hepatocellular Carcinoma - Pipeline by Raptor Pharmaceutical Corp., H1 2016 171 Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd., H1 2016 172 Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc., H1 2016 173 Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H1 2016 174 Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology, Inc., H1 2016 175 Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd., H1 2016 176 Hepatocellular Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 177 Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016 178 Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 179 Hepatocellular Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 180 Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc., H1 2016 181 Hepatocellular Carcinoma - Pipeline by Theravectys SA, H1 2016 182 Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 183 Hepatocellular Carcinoma - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016 184 Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 185 Hepatocellular Carcinoma - Pipeline by Tumorend, LLC, H1 2016 186 Hepatocellular Carcinoma - Pipeline by UbiVac, LLC, H1 2016 187 Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics, Inc., H1 2016 188 Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H1 2016 189 Hepatocellular Carcinoma - Pipeline by Vect-Horus S.A.S., H1 2016 190 Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc., H1 2016 191 Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics, LLC, H1 2016 192 Hepatocellular Carcinoma - Pipeline by Virttu Biologics Limited, H1 2016 193 Hepatocellular Carcinoma - Pipeline by Vyriad, H1 2016 194 Assessment by Monotherapy Products, H1 2016 195 Assessment by Combination Products, H1 2016 196 Number of Products by Stage and Target, H1 2016 198 Number of Products by Stage and Mechanism of Action, H1 2016 206 Number of Products by Stage and Route of Administration, H1 2016 213 Number of Products by Stage and Molecule Type, H1 2016 215 Hepatocellular Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016 636 Hepatocellular Carcinoma - Dormant Projects, H1 2016 939 Hepatocellular Carcinoma - Dormant Projects (Contd..1), H1 2016 940 Hepatocellular Carcinoma - Dormant Projects (Contd..2), H1 2016 941 Hepatocellular Carcinoma - Dormant Projects (Contd..3), H1 2016 942 Hepatocellular Carcinoma - Dormant Projects (Contd..4), H1 2016 943 Hepatocellular Carcinoma - Dormant Projects (Contd..5), H1 2016 944 Hepatocellular Carcinoma - Dormant Projects (Contd..6), H1 2016 945 Hepatocellular Carcinoma - Dormant Projects (Contd..7), H1 2016 946 Hepatocellular Carcinoma - Dormant Projects (Contd..8), H1 2016 947 Hepatocellular Carcinoma - Dormant Projects (Contd..9), H1 2016 948 Hepatocellular Carcinoma - Dormant Projects (Contd..10), H1 2016 949 Hepatocellular Carcinoma - Discontinued Products, H1 2016 950 Hepatocellular Carcinoma - Discontinued Products (Contd..1), H1 2016 951 Hepatocellular Carcinoma - Discontinued Products (Contd..2), H1 2016 952


List of Figures
Number of Products under Development for Hepatocellular Carcinoma, H1 2016 34 Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H1 2016 35 Number of Products under Development by Companies, H1 2016 36 Number of Products under Investigation by Universities/Institutes, H1 2016 46 Comparative Analysis by Clinical Stage Development, H1 2016 49 Comparative Analysis by Early Stage Products, H1 2016 50 Assessment by Monotherapy Products, H1 2016 195 Assessment by Combination Products, H1 2016 196 Number of Products by Top 10 Targets, H1 2016 197 Number of Products by Stage and Top 10 Targets, H1 2016 197 Number of Products by Top 10 Mechanism of Actions, H1 2016 205 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 205 Number of Products by Top 10 Routes of Administration, H1 2016 212 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 212 Number of Products by Top 10 Molecule Types, H1 2016 214 Number of Products by Stage and Top 10 Molecule Types, H1 2016 214

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify